Altesa BioSciences
College Park, US · Founded 2020 · Delaware corporation · 6 known investors
Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma. The drug aims to stop viral infections before they trigger acute respiratory exacerbations, addressing the underlying viral cause rather than downstream inflammation.
Founders & leadership
Board
NW
MS
JE
Jon EdwardsBoard director
IH
SR
Investors · 6
GRA VentureGeorgia
Forbionreported · 2 sourcesNaarden
Medicxireported · 3 sourcesLondonvia Moncef Slaoui · board
Pitangoreported · 3 sourcesTel Aviv · $4M – $100Mvia Ittai Harel · board
Also in the syndicate · 2
Atlantic PartnersSanofi
Reported raises · per SEC filings
Form D private placements$110M disclosed across 2 rounds · 2022–2026
▶$75MraisedFeb 2026 · 17 investors · PharmaceuticalsRule 506(b)
▶$75MraisedFeb 2026 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John ClericiExecutive Officer
- Nicholas WilliamsDirector
- Moncef SlaouiDirector
- Andrew DrechslerExecutive Officer
- Seth RudnickDirector
- Jon EdwardsDirector
- Brett GiroirExecutive Officer, Director
- Ittai HarelDirector
- Offering amount
- $75M
- Amount sold
- $75M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35MraisedJul 2023 · 18 investors · PharmaceuticalsRule 506(b)
▶$35MraisedJul 2023 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brett GiroirExecutive Officer, Director
- Ittai HarelDirector
- Moncef SlaouiDirector
- Seth RudnickDirector
- Nicholas WilliamsDirector
- John ClericiExecutive Officer
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Atropos Health4 shared keywordsAtropos Health develops a cloud-based platform that generates real-world evidence from electronic health records to inform clinical decision-making and healthcare research. The company enables healthcare institutions, clinicians, and life sciences organizations to rapidly conduct observational studies from patient data for personalized medicine and evidence-based practice.
Alesta4 shared keywordsAlesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology. The biotech company works on early-stage drug development and clinical research.
Companies competing with Altesa BioSciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Altesa BioSciences Named Recipient of the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the Year - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does Altesa BioSciences do?
- Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma. The drug aims to stop viral infections before they trigger acute respiratory exacerbations, addressing the underlying viral cause rather than downstream inflammation.
- Who are Altesa BioSciences's investors?
- Altesa BioSciences's investors include GRA Venture, Forbion, Medicxi, Pitango.
- How much funding has Altesa BioSciences raised?
- Altesa BioSciences has disclosed $110M raised across 2 rounds.
- Where is Altesa BioSciences headquartered?
- Altesa BioSciences is headquartered in College Park, US.